Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 21 January 2022, including: GlaxoSmithKline plc’s R&D head departs; Bayer AG’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax S.A. an M&A target; and China’s gene therapy developers rush to clinic.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Hal Barron To Depart GSK To Head Up New Biotech" - Scrip, 19 Jan, 2022.)
(Also see "Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space" - Scrip, 17 Jan, 2022.)
(Also see "France's Abivax Looks A Likely M&A Target" - Scrip, 14 Jan, 2022.)
(Also see "China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle" - Scrip, 18 Jan, 2022.)